本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Akari Therapeutics PLC

0.8191
+0.00670.82%
盤後0.81910.00000.00%16:10 EDT
成交量:2.06萬
成交額:1.69萬
市值:2,671.47萬
市盈率:-1.51
高:0.8340
開:0.8201
低:0.8001
收:0.8124
52周最高:3.85
52周最低:0.5714
股本:3,261.47萬
流通股本:562.08萬
量比:0.03
換手率:0.37%
股息:- -
股息率:- -
每股收益(TTM):-0.5428
每股收益(LYR):-1.6570
淨資產收益率:-112.02%
總資產收益率:-28.56%
市淨率:1.04
市盈率(LYR):-0.49

資料載入中...

2024/05/16

重要事件披露

Form 8-K - Current report
2024/05/15

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/07

重要事件披露

Form 8-K - Current report
2024/05/01

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/05/01

重要事件披露

Form 8-K - Current report
2024/04/11

重要事件披露

Form 8-K - Current report
2024/04/01

重要事件披露

Form 8-K - Current report
2024/03/29

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/11

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/03/11

重要事件披露

Form 8-K - Current report
2024/03/05

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/03/05

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2024/03/05

重要事件披露

Form 8-K - Current report
2024/01/05

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/01/03

重要事件披露

Form 8-K - Current report
2023/10/25

SEC問詢函

Form CORRESP - Correspondence
2023/10/20

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/10/13

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/31

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/01

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]